Transcatheter Papillary Muscle Repositioning, Cardiac Success Ltd.

Background: 21 million patients worldwide are living with heart failure. It is a devastating disease with severe symptoms that lead to mortality rates of 50% within 5 years from diagnosis. Heart failure is the number 1 cause of rehospitalization

Our Solution: Cardiac Success is developing the first percutaneous ventricular repair system designed to treat heart failure by papillary muscle repositioning.
We treat heart failure associated with geometrical remodeling of the left ventricle by transfemoral delivery of a proprietary sling implant that
repositions the papillary muscles and reshapes the left ventricle. Papillary muscle repositioning has demonstrated clinical value including long term
follow up using the surgical papillary muscle sling procedure.

ADVANTAGES
• Leveraging existing clinical efficacy of a surgical papillary muscle sling
procedure
• Treating ventricular dilation directly at its source by repositioning the
papillary muscles
• Adjustable implant size for optimized papillary muscle repositioning
using real time echo doppler
• Sheathless transfemoral approach using our low-profile delivery system
• Safe anchorless implant without endocardium penetration.
• Implant does not block future interventions

Product Status
Advanced proof of concept:
• Chronic animals
• Transcatheter procedures in animal model
• Transcatheter Cadaver studies
• Fatigue tests
Fisrt In Human planned for 2021

Intellectual property: 2 granted US patents + 1 allowed patent and more patents in assorted stages.